PE20141009A1 - Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, o una sal de la misma - Google Patents

Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, o una sal de la misma

Info

Publication number
PE20141009A1
PE20141009A1 PE2013002132A PE2013002132A PE20141009A1 PE 20141009 A1 PE20141009 A1 PE 20141009A1 PE 2013002132 A PE2013002132 A PE 2013002132A PE 2013002132 A PE2013002132 A PE 2013002132A PE 20141009 A1 PE20141009 A1 PE 20141009A1
Authority
PE
Peru
Prior art keywords
naphthamide
imidazol
dihydro
hydroxy
methyl
Prior art date
Application number
PE2013002132A
Other languages
English (en)
Inventor
Wataru Hoshina
Masafumi Misaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46018066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141009(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20141009A1 publication Critical patent/PE20141009A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDO A UNA PREPARACION SOLIDA QUE COMPRENDE: A) 6-((7S)-7-HIDROXI-6,7-DIHIDRO-5H-PIRROLO[1,2-C]IMIDAZOL-7-IL)-N-METIL-2-NAFTAMIDA O UNA DE SUS SALES, CON UN CONTENIDO DEL 50-80% EN PESO; B) D-MANITOL Y, C) UNA SAL DE METAL ALCALINOTERREO SELECCIONADA DE ALUMINOMETASILICATO DE MAGNESIO Y SILICATO DE CALCIO. ADEMAS DICHA PREPARACION COMPRENDE HIDROXIPROPILCELULOSA
PE2013002132A 2011-04-01 2012-03-29 Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, o una sal de la misma PE20141009A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011082301 2011-04-01

Publications (1)

Publication Number Publication Date
PE20141009A1 true PE20141009A1 (es) 2014-09-04

Family

ID=46018066

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002132A PE20141009A1 (es) 2011-04-01 2012-03-29 Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, o una sal de la misma

Country Status (28)

Country Link
US (3) US20150157609A1 (es)
EP (1) EP2694039B1 (es)
JP (1) JP6077459B2 (es)
KR (1) KR20140018923A (es)
CN (1) CN103458878B (es)
AR (1) AR085743A1 (es)
AU (1) AU2012233203A1 (es)
BR (1) BR112013022010A2 (es)
CA (1) CA2831548A1 (es)
CL (1) CL2013002579A1 (es)
CO (1) CO6821945A2 (es)
CR (1) CR20130481A (es)
DO (1) DOP2013000217A (es)
EA (1) EA201391447A1 (es)
EC (1) ECSP13012905A (es)
ES (1) ES2607070T3 (es)
GE (1) GEP20156306B (es)
IL (1) IL228357A0 (es)
MA (1) MA35069B1 (es)
MX (1) MX2013010661A (es)
PE (1) PE20141009A1 (es)
PH (1) PH12013502038B1 (es)
SG (1) SG193328A1 (es)
TN (1) TN2013000356A1 (es)
TW (1) TW201244757A (es)
UY (1) UY33996A (es)
WO (1) WO2012133918A1 (es)
ZA (1) ZA201306799B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112206218B (zh) * 2020-10-24 2022-08-23 迪沙药业集团有限公司 一种甲硝唑维生素b6组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3145146A (en) * 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
ES2260303T3 (es) 2000-11-17 2006-11-01 Takeda Pharmaceutical Company Limited Derivados de imidazol, metodo para su produccion, y su uso.
JP2002308760A (ja) * 2001-04-06 2002-10-23 Taiyo Yakuhin Kogyo Kk 圧縮成型用組成物及びその利用
WO2004075890A1 (ja) 2003-02-26 2004-09-10 Takeda Pharmaceutical Company 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾ－ル誘導体の安定化方法
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
EP1607092A4 (en) 2003-03-17 2010-12-15 Takeda Pharmaceutical COMPOSITIONS WITH CONTROLLED RELEASE
WO2006093353A1 (ja) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
JP2011082301A (ja) 2009-10-06 2011-04-21 Sony Corp 配線基板、その製造方法および電子機器

Also Published As

Publication number Publication date
GEP20156306B (en) 2015-06-25
CN103458878A (zh) 2013-12-18
CL2013002579A1 (es) 2014-01-24
MA35069B1 (fr) 2014-04-03
EA201391447A1 (ru) 2014-02-28
AU2012233203A1 (en) 2013-10-10
US20150157609A1 (en) 2015-06-11
EP2694039A1 (en) 2014-02-12
TW201244757A (en) 2012-11-16
MX2013010661A (es) 2013-10-28
ECSP13012905A (es) 2013-11-29
KR20140018923A (ko) 2014-02-13
NZ615452A (en) 2015-05-29
UY33996A (es) 2012-10-31
BR112013022010A2 (pt) 2016-11-29
CO6821945A2 (es) 2013-12-31
ZA201306799B (en) 2014-11-26
PH12013502038B1 (en) 2019-07-17
DOP2013000217A (es) 2013-12-31
IL228357A0 (en) 2013-12-31
CR20130481A (es) 2013-10-23
CN103458878B (zh) 2015-11-25
CA2831548A1 (en) 2012-10-04
EP2694039B1 (en) 2016-09-21
US20170202777A1 (en) 2017-07-20
JP6077459B2 (ja) 2017-02-08
PH12013502038A1 (en) 2013-12-16
WO2012133918A1 (en) 2012-10-04
SG193328A1 (en) 2013-10-30
AR085743A1 (es) 2013-10-23
JP2014509586A (ja) 2014-04-21
TN2013000356A1 (en) 2015-01-20
ES2607070T3 (es) 2017-03-29
US20190054026A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
PE20140978A1 (es) Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla
CR20150174A (es) Composición esterilizada que comprende al menos un ácido hialuronico y ascorbil fosfato de magnesio
AR093794A1 (es) Composiciones conteniendo fosfato de zinc
PE20151654A1 (es) Inhibidores de cdc7
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
BR112018075250A2 (pt) composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
MX388893B (es) Formulaciones de anticuerpos estables acuosas.
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
MX356091B (es) Composiciones de escoria que comprenden látex y métodos de uso.
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
MX2016008668A (es) Composiciones de fosforo resistentes a la humedad y metodos asociados.
MA44550B1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
EA201892729A1 (ru) Гемисульфатная соль 5,10-метилен-(6r)-тетрагидрофолиевой кислоты
BR112014000293A2 (pt) aglutinante hidráulico
CL2016001546A1 (es) Composición para el cuidado oral que comprende serina y al menos una sal de zinc.
UY34436A (es) Metodo de control del peso
AR095991A1 (es) Indicador de desgaste en un sistema compuesto hecho de ladrillos de cerámica ignífugos
MX2016016613A (es) Composicion en forma de particulas compactadas y su uso.
PE20141009A1 (es) Preparacion solida que comprende 6-((7s)-7-hidroxi-6,7-dihidro-5h-pirrolo[1,2-c]imidazol-7-il)-n-metil-2-naftamida, o una sal de la misma
BR112017023880A2 (pt) sais de polifosfato de cálcio, métodos de produção e uso em composições de bebida
UY34990A (es) Preparación que contiene potasio, proceso para su producción y uso
MX2016005428A (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.
AR099213A1 (es) Método y composición para reducir las incrustaciones en base a sílice del evaporador
EA201300031A1 (ru) Системы и способы вычисления стандартной 3d вариограммной модели

Legal Events

Date Code Title Description
FD Application declared void or lapsed